DK0696198T3 - Nyt polypeptid, der har inhiberende virkning mod faktor Xa - Google Patents

Nyt polypeptid, der har inhiberende virkning mod faktor Xa

Info

Publication number
DK0696198T3
DK0696198T3 DK94914087T DK94914087T DK0696198T3 DK 0696198 T3 DK0696198 T3 DK 0696198T3 DK 94914087 T DK94914087 T DK 94914087T DK 94914087 T DK94914087 T DK 94914087T DK 0696198 T3 DK0696198 T3 DK 0696198T3
Authority
DK
Denmark
Prior art keywords
polypeptide
novel polypeptide
inhibitory effect
effect against
against factor
Prior art date
Application number
DK94914087T
Other languages
English (en)
Inventor
Elisha P Zeelon
Moshe M Werber
Avigdor Levanon
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of DK0696198T3 publication Critical patent/DK0696198T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • A61K38/58Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94914087T 1993-04-09 1994-04-08 Nyt polypeptid, der har inhiberende virkning mod faktor Xa DK0696198T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4580593A 1993-04-09 1993-04-09
PCT/US1994/003871 WO1994023735A1 (en) 1993-04-09 1994-04-08 Novel polypeptide having factor xa inhibitory activity

Publications (1)

Publication Number Publication Date
DK0696198T3 true DK0696198T3 (da) 2001-08-06

Family

ID=21939985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914087T DK0696198T3 (da) 1993-04-09 1994-04-08 Nyt polypeptid, der har inhiberende virkning mod faktor Xa

Country Status (15)

Country Link
EP (1) EP0696198B1 (da)
JP (1) JPH08511157A (da)
KR (1) KR960701649A (da)
AT (1) ATE198710T1 (da)
AU (1) AU682361B2 (da)
CA (1) CA2159218A1 (da)
DE (1) DE69426598T2 (da)
DK (1) DK0696198T3 (da)
ES (1) ES2155472T3 (da)
GR (1) GR3035722T3 (da)
HK (1) HK1013315A1 (da)
IL (1) IL109259A0 (da)
NZ (1) NZ265507A (da)
PT (1) PT696198E (da)
WO (1) WO1994023735A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
HU229626B1 (hu) 2005-04-11 2014-03-28 Savient Pharmaceuticals Urát oxidáz változat és alkalmazása
CA2604399A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US8784896B2 (en) 2012-09-17 2014-07-22 Biopep Solutions, Inc Antioxidant therapy with a whole, leech saliva extract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
EP0347376B1 (en) * 1988-06-11 1994-03-23 Ciba-Geigy Ag Novel polypeptides with an anticoagulant activity
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
CA2159218A1 (en) 1994-10-27
GR3035722T3 (en) 2001-07-31
NZ265507A (en) 1998-09-24
IL109259A0 (en) 1994-07-31
KR960701649A (ko) 1996-03-28
PT696198E (pt) 2001-07-31
EP0696198B1 (en) 2001-01-17
EP0696198A4 (en) 1999-01-27
AU6629194A (en) 1994-11-08
EP0696198A1 (en) 1996-02-14
WO1994023735A1 (en) 1994-10-27
HK1013315A1 (en) 1999-08-20
DE69426598D1 (de) 2001-02-22
JPH08511157A (ja) 1996-11-26
DE69426598T2 (de) 2001-08-09
ATE198710T1 (de) 2001-02-15
AU682361B2 (en) 1997-10-02
ES2155472T3 (es) 2001-05-16

Similar Documents

Publication Publication Date Title
DE69128779D1 (de) Epitheline: neue cystein-reiche, den wachstum modulierende proteine
DK0696198T3 (da) Nyt polypeptid, der har inhiberende virkning mod faktor Xa
DE69224237T2 (de) Bakteriocin von Lactococcus Lactis Subspezies Lactis
PL307258A1 (en) Peptides capable to block calcium canals with agelenopsis aperta
GR3025857T3 (en) Molecular cloning and expression of human IL-3
PL307726A1 (en) Inhibitor of collagen stimulated aggregation of thrombocites
CA2093819A1 (en) Platelet adhesion inhibitor
DE69205154D1 (de) Verwendung von mindestens einem gereinigten peptid, welches durch kaseinhydrolyse hergestellt werden kann und opiataktivität hat, als aktiven bestandteil in der herstellung einer kosmetischen zusammensetzung.
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
CA2375224A1 (en) Human antithrombin variants
Rawczynska-Englert et al. Staphylococcal endocarditis after valve replacement(9 years of experience).
RU93034458A (ru) Композиция гемоглобина, поперечно связанного с имидоэфиром, и способ ее получения